MacroGenics(MGNX) - 2023 Q4 - Annual Results

Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and 2023 Financial Results ROCKVILLE, MD., Mar 7, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023. "We expect that 2024 will be an important year f ...